



# YungShin Global Holding Corporation Investor Conference

**Provide the best products  
to improve human health**

---

**Sep. 20, 2024**



[www.yungshingroup.com](http://www.yungshingroup.com)



# Disclaimers

This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there are a variety of factors which could cause actual results to differ materially from those statements. Therefore, please refer to the information on MOPS website as the main basis if any adjustment has been made. (<http://mops.twse.com.tw/mops/web/index>)





# Table of Contents

---




- **YungShin Group Overview**
- **Operational Results for first half year of 2023**
- **Business Strategy**





# Introduction of YungShin Group

A pharmaceutical Group have been established over 60 years, looking forward being a-century enterprise.





# Listing History

Three subsidiaries list in TW, CN and MY.

- 1993- Listing of Yungshin Pharmaceutical, Taiwan



臺灣證券交易所

- 2000-Listing of Yung Zip Chemical, Taiwan



證券櫃檯買賣中心  
Taipei Exchange

- 2004-Listing of Y.S.P. Southeast Asia Holding, Malaysia



- 2011-Listing of YungShin Global Holding, Taiwan



臺灣證券交易所

- 2023-Listing of Vetnostrum, Taiwan emerging stock market



證券櫃檯買賣中心  
Taipei Exchange




[www.yungshingroup.com](http://www.yungshingroup.com)





# R&D and Production Planning Worldwide

Night manufacturing and operating bases cross US, CN, JP and South Asia.





# YungShin Group Main Production Bases(1/2)

Subsidiaries in TW and US have been certified by USFDA.

Production bases of YSG have covered 5 continents and products sold over 35 countries.



1990  
Yung Zip  
(Taiwan)



1998  
Carlsbad  
(USA)



2004  
YungShin  
(Taiwan)







# YungShin Group Main Production Bases(2/2)

MY, VN and IN sites have exported to Southeast Asia, middle East, North Africa and Oceania.



(Malaysia)



(Vietnam)



(Indonesia)



(Malaysia)



NATIONAL  
PHARMACEUTICAL  
REGULATORY  
AGENCY



Health  
Canada

Santé  
Canada



Australian Government

Department of Health

Therapeutic Goods Administration



衛生福利部  
食品藥物管理署  
Taiwan Food and Drug Administration



TGA Health Safety  
Regulation




www.yungshingroup.com





# YSH Stable Business

Stable payout dividend in every economy cycle





# Operational Results for first half year of 2024

**Provide the best products  
to improve human health**

---





# YSH Consolidated Statements of Income

Comparing Profit before income tax increased by 66.92% and profit for the period increased by 68.38%% for first half year of 2024 and 2023.

(Expressed in millions of NTD)

	2024H1	2023H1	Growth rate
Operating revenue	3,772	3,363	12.16
Operating costs	(2,102)	(1,934)	8.69
Gross profit	1,670	1,429	16.86
Operating expenses	(1,042)	(990)	5.25
Income from operations	628	439	43.05
Non-operating income & Expenses	250	87	187.36
Profit before income tax	878	526	66.92
Profit for the period	655	389	68.38
Earnings per share	2.26	1.41	60.28





# YSH Consolidated balance sheet (1/2)

Comparing total assets increased by 15.31% in 2024 and 2023.

(Expressed in millions of NTD)

	2024H1	%	2023H1	%
Cash and cash equivalents	1,699	13	1,927	17
Inventories	3,018	23	2,724	23
Accounts receivable	1,784	13	1,465	12
Other current assets	576	3	399	4
Property, plant and equipment	4,597	36	3,611	31
Other non-current assets	1,708	12	1,479	13
<b>Total assets</b>	<b>13,382</b>	<b>100</b>	<b>11,605</b>	<b>100</b>



# YSH Consolidated balance sheet (2/2)

Comparing total shareholder's equity increased by 22.69% in 2024 and 2023.

(Expressed in millions of NTD)

	2024H1	%	2023H1	%
Short-term borrowings	634	6	946	8
Other current liabilities	2,369	17	1,985	17
Long-term borrowings	298	2	243	2
Non-current liabilities	952	7	990	9
Total shareholder's equity	9,129	68	7,441	64
Total liabilities and	13,382	100	11,605	100





# YSH Consolidated Operating Revenue by area

Comparing consolidated revenue increased by 12.17% for first half year of 2024 and 2023.

(Expressed in thousands of local currency)

	Currency	2024H1	2023H1	Growth rate
Taiwan	TWD	2,909,205	2,722,228	6.87
USA	USD	13,310	8,501	56.57
China	RMB	7,374	9,860	-25.21
Japan	JPY	1,932,931	1,488,489	29.86

1. The list the revenues of companies that YSH holding only more than 50% shares.
2. Operating revenue by area is based on financial report, and the growth rate is calculated in local currency.





# Business Strategy

**Provide the best products  
to improve human health**

---





# Operating Strategy of YSH

Eight aspects to accomplish steady investment and pragmatic operation for creating the best interests of shareholders.





# Business Strategy of YSH

Internal investment management and external M&A for strengthening group efficiency

The strategy will balance short, medium and long term group development and shareholders' equity



## Internal investment management

### •Production

Cross company platform communication and production experience optimization

### •Marketing

Search, supply, marketing promotion transnationally

### •Personnel(ESG)

Integrate experiences communication of joint factory inspection for national laws and regulations

### •R&D

Project coordination, R&D technology transfer reducing investment

### •Finance

Supervising by YSH, apply endorsement and guarantee to reduce financial burden and increase investment efficiency



## External M&A



### •New business

1. Obtaining factories, products and technologies and enter into the market of feed additives by merger and acquisition of Pfizer Inc.(Hsinchu plant)
2. Multi-angle consideration relating to health industry

### •New market

1. Entering into OEM business by merger and acquisition of Alpha-Active and Taiwan Wa- Chein Ind. Co., Ltd.
2. New market evaluation such as in Europe...etc.

### •New product/technology

1. Obtain manufacturing technology from GlyTech Inc.
2. Evaluating biological medicine, cell therapy and other fields.



# Yung Zip Chemical IND CO., LTD


## Book in financial report from Jun 2025



Founded on June 8, 1978, and rooted in the active pharmaceutical ingredient industry for over 40 years, we are the first domestic pharmaceutical ingredient manufacturer to obtain GMP certification from the Taiwan Department of Health. We have also successively passed international certifications from US FDA, MHRA, PMDA, KFDA, HALAL, and KOSHER.

**In response to changing international circumstances, the company is seeking growth and transformation opportunities to build a continuous growth engine.**

### Development







# CarlsbadTech (YungShin US)

Total solution from production to marketing as window for Asia company to enter US market.



## History:

*Company started in 1990 and facility operated in 1998.*

## Location:

*Located 30 miles north of San Diego, 130 miles south of LAX, 90 miles from Port of Los Angeles.*



Production



Labatory

## Space:

*cGMP compliance solid dosage form manufacturing facility (Approx. 21,000 sq.ft.).*

## Production Capability:

*About 800mio to 1,000mio tabs capacity per year.*

## Customer:

*Cover US 96% customers in sales channel with 50 stats selling permit.*

## Product:

*Diclofenac · Acyclovir · Famotidine and Lovastatin etc.*





# Create New Value for Share Holder Enter Capital Market



Wyeth



zoetis



Cyana  
mid

Wyeth

Pfizer

Zotis

Vetnostrum

1960  
built

1994  
Wyeth  
acquire  
Cyanamid

2010  
Pfizer  
acquire  
Wyeth

2014  
Zoetis  
independent  
from Pfizer

2016  
YSP acquire  
Zoetis TW to  
build Vetnostrum

2017  
Vetnostrum  
merge YSP  
animal  
division

2020  
Launch new  
brand

2023Q3  
IPO  
apply

歐羅肥®

TW only high potency and general inj. Manufacture

## 一般針劑生產線

產品 Lincosamides, Triamcinolone acetone, Tolfenamic acid...  
產能 2,100,000瓶/年  
■ 2019 設立 ■ Isolator 無菌檢驗實驗室  
■ 液體充填機 ■ 氮氣填充壓機



液體充填機



Isolator 無菌檢驗實驗室



氮氣充氮隧道

## 高致敏針劑生產線


產品 Amoxicillin, Cephalosporins...  
產能 1,125,000瓶/年  
■ 2019 設立 ■ 高效能密封式封蓋系統  
■ 底部式烘箱 ■ 精準電子秤重系統



隧道式烘箱(去熱原)



高效能密封式封蓋系統



精準電子秤重系統



www.yungshingroup.com



# Maximize Value Chain Based on Product

Strengthen the competitiveness of the group through vertical integration and horizontal expansion



## Maximize Value Chain

### Vertical integration : Maximize Production Value Chain

- Vertical integration of main products through manufacturing and marketing of intermediate, API and FDF.
- Master raw material intermediate suppliers through investment and contract manufacture.
- Local production reduce the risk of trade barriers.
- Sharing R&D resource from in Taiwan and Malaysia lab.
- Continually strengthen product line competitiveness (integrate value chain and expand production batch size)


### Horizontal expansion : Maximize Sales Value Chain

- Future product lines drive from market orientation
- Deep development of digestive tract, pain, hypersensitivity and anticancer fields.
- Increasing investment benefit through Integration product lines in various countries, mutual distribution, technology transfer, and development together.
- Expansion of four major business: API, FDF, OTC and animal drugs



# Diversified Business Map

Expansion and exposure new business based on core health care relative business







# Core Value of YungShin Group

## Provide the best products to improve human health from Taiwan



### Spirit of YungShin Group :

We produce medicine that we would give it to our own families.

We establish Nursing Home that our elders would love to go to.

Social welfare covered by cooperate social responsibility





# Q&A

**Provide the best products  
to improve human health**

---

